aMoon fund leads investment round in Nectin Therapeutics with initial closing of $6m, total investment expected to reach $15m Nectin will use the funding for further development of its next-generation immuno-oncology antibodies that help the immune system fight cancer. aMoon Velocity, the early-stage fund of Israel’s largest HealthTech and life sciences venture fund aMoon, today announced...Read More